PubMed HealthSearch

PubMed · 7701846

[Do light cigarettes decrease the risk of smoking?].

Abstract

Since the introduction of filter cigarettes in the sixties and early seventies, a reduction of the risk for lung cancer could be observed (20 to 40%). However, a further reduction of tobacco smoke ingredients by smoking modern light cigarettes (tar content below 10 mg) is questionable because of compensation of smoking behaviour by the individual smoker. A further reduction of risk to contract lung cancer by smoking light cigarettes therefore is not probable and supportive data are not available. Smoking of light cigarettes is not likely to result in a significant decrease of the risk for myocardial infarction or cardiac death as well as for chronic lung diseases. Promotion of light cigarettes by the tobacco industry is suggesting that each smoker could significantly diminish his risks just by selecting the right type of cigarettes. This is not supported by long term clinical studies. Such promotion, however, provides the smoker with further arguments to continue smoking. Ultra light cigarettes (tar content below 3 mg) could potentially diminish the risk but are hardly accepted by current smokers. Despite strong promotion and advertisement ultra light cigarettes had not been successful on the market.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Klech. 1994. [Do light cigarettes decrease the risk of smoking?].. https://pubmed.ncbi.nlm.nih.gov/7701846/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Edg-2/Vzg-1 couples to the yeast pheromone response pathway selectively in response to lysophosphatidic acid.

We have functionally expressed the human cDNA encoding the putative lysophosphatidic acid (LPA) receptor Edg-2 (Vzg-1) in Saccharomyces cerevisiae in an attempt to determine the agonist specificity of this G-protein-coupled receptor. LPA activated the pheromone response pathway in S. cerevisiae expressing Edg-2 in a time- and dose-dependent manner as determined by induction of a pheromone-responsive FUS1::lacZ reporter gene. LPA-mediated activation of the pheromone response pathway was dependent on mutational inactivation of the SST2 gene, the GTPase-activating protein for the yeast G alpha protein (the GPA1 gene product). This indicates that, in sst2 delta yeast cells, Edg-2 can efficiently couple to the yeast heterotrimeric G-protein in response to LPA and activate the yeast mitogen-activated protein kinase pathway. The Edg-2 receptor showed a high degree of specificity for LPA; other lyso-glycerophospholipids, sphingosine 1-phosphate, and diacyl-glycerophospholipids did not activate FUS1::lacZ. LPA analogs including a cyclic phosphoester form and ether-linked forms of LPA activated FUS1::lacZ, although fatty acid chains of 6 and 10 carbons did not activate FUS1::lacZ, suggesting a role for the side chain in ligand binding or receptor activation. These results indicate that Edg-2 encodes a highly specific LPA receptor.

Dose-Response Relationship, Drug

Integrated functions for four basic models of indirect pharmacodynamic response.

The integrated solutions (ABEC, area between baseline and effect curve) of four basic models of indirect pharmacodynamic responses are developed. These models assume that drug can inhibit or stimulate the production or loss of the response variable. For two models (I and III) with monoexponential drug disposition, explicit formulas for the ABEC were obtained, where ABEC is a function of ln (1 + (D/V)/IC50) or ln (1 + (D/V)/SC50) where D = dose, V = volume, and IC50 or SC50 = 50% effective concentration. Two other models (II and IV) were treated asymptotically with respect to small and large doses. Approximate formulas [e.g., ABEC = constant(1) x ln (1 + (D/V)/IC50) + constant (2)] were derived and the asymptotic behavior of the ABEC was established. In addition, simulations were performed to assess the effects of drug absorption rates and polyexponential disposition on ABEC values. These models show how pharmacokinetic and pharmacodynamic factors jointly determine the net response to a single dose of drug.

Dose-Response Relationship, Drug

A review of tests for detecting a monotone dose-response relationship with ordinal response data.

This tutorial reviews methods for testing independence between discrete levels of a dose and an ordered categorical response variable. The tests are designed to be powerful for cases in which the response improves monotonically as dosage level increases. First, we show how to apply some standard tests for doubly-ordered contingency tables. Then, we show how to construct tests as part of a model-building strategy. Other topics discussed include generalizations to stratified data, small-sample methods, and sample size and power considerations.

Dose-Response Relationship, Drug